{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:37:38Z","timestamp":1785789458240,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1038\/s41401-019-0329-2","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T10:02:38Z","timestamp":1578391358000},"page":"782-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Ganoderic acid A is the effective ingredient of Ganoderma triterpenes in retarding renal cyst development in polycystic kidney disease"],"prefix":"10.1038","volume":"41","author":[{"given":"Jia","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sai-zhen Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-zhao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-qian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"key":"329_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393:919\u201335.","journal-title":"Lancet"},{"key":"329_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88:17\u201327.","journal-title":"Kidney Int"},{"key":"329_CR3","doi-asserted-by":"crossref","unstructured":"Consortium T. I. P. K. D. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. Cell. 1995;81:289\u201398.","DOI":"10.1016\/0092-8674(95)90339-9"},{"key":"329_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","volume":"272","author":"T Mochizuki","year":"1996","unstructured":"Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272:1339\u201342.","journal-title":"Science"},{"key":"329_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","volume":"60","author":"PC Harris","year":"2009","unstructured":"Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009;60:321\u201337.","journal-title":"Annu Rev Med"},{"key":"329_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.krcp.2014.05.002","volume":"33","author":"SH Lee","year":"2014","unstructured":"Lee SH, Somlo S. Cyst growth, polycystins, and primary cilia in autosomal dominant polycystic kidney disease. Kidney Res Clin Pract. 2014;33:73\u20138.","journal-title":"Kidney Res Clin Pract"},{"key":"329_CR7","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1681\/ASN.2012070650","volume":"24","author":"E Cornec-Le Gall","year":"2013","unstructured":"Cornec-Le Gall E, Audrezet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24:1006\u201313.","journal-title":"J Am Soc Nephrol"},{"key":"329_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1053\/j.ajkd.2014.05.020","volume":"64","author":"S Reule","year":"2014","unstructured":"Reule S, Sexton DJ, Solid CA, Chen SC, Collins AJ, Foley RN. ESRD from autosomal dominant polycystic kidney disease in the United States, 2001\u20132010. Am J Kidney Dis. 2014;64:592\u20139.","journal-title":"Am J Kidney Dis"},{"key":"329_CR9","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong AC, Devuyst O, Knebelmann B, Walz G. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385:1993\u20132002.","journal-title":"Lancet"},{"key":"329_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2215\/CJN.01520218","volume":"13","author":"ME Edwards","year":"2018","unstructured":"Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018;13:1153\u201361.","journal-title":"Clin J Am Soc Nephrol"},{"key":"329_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrneph.2017.127","volume":"13","author":"MB Lanktree","year":"2017","unstructured":"Lanktree MB, Chapman AB. New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017;13:750\u201368.","journal-title":"Nat Rev Nephrol"},{"key":"329_CR12","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.kint.2017.04.013","volume":"92","author":"L Su","year":"2017","unstructured":"Su L, Liu L, Jia Y, Lei L, Liu J, Zhu S, et al. Ganoderma triterpenes retard renal cyst development by downregulating Ras\/MAPK signaling and promoting cell differentiation. Kidney Int. 2017;92:1404\u201318.","journal-title":"Kidney Int"},{"key":"329_CR13","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1021\/np300412h","volume":"75","author":"JL Rios","year":"2012","unstructured":"Rios JL, Andujar I, Recio MC, Giner RM. Lanostanoids from fungi: a group of potential anticancer compounds. J Nat Prod. 2012;75:2016\u201344.","journal-title":"J Nat Prod"},{"key":"329_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1517\/13543784.2013.805202","volume":"22","author":"GS Wu","year":"2013","unstructured":"Wu GS, Guo JJ, Bao JL, Li XW, Chen XP, Lu JJ, et al. Anti-cancer properties of triterpenoids isolated from Ganoderma lucidum\u2014a review. Expert Opin Investig Drugs. 2013;22:981\u201392.","journal-title":"Expert Opin Investig Drugs"},{"key":"329_CR15","doi-asserted-by":"publisher","first-page":"14271","DOI":"10.1007\/s13277-016-5291-8","volume":"37","author":"BS Gill","year":"2016","unstructured":"Gill BS, Navgeet, Kumar S. Ganoderic acid targeting multiple receptors in cancer: in silico and in vitro study. Tumour Biol. 2016;37:14271\u201390.","journal-title":"Tumour Biol"},{"key":"329_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s10637-017-0526-0","volume":"36","author":"BS Gill","year":"2018","unstructured":"Gill BS, Navgeet, Mehra R, Kumar V, Kumar S. Ganoderic acid, lanostanoid triterpene: a key player in apoptosis. Investig New Drugs. 2018;36:136\u201343.","journal-title":"Investig New Drugs"},{"key":"329_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00253-010-2576-5","volume":"87","author":"JW Xu","year":"2010","unstructured":"Xu JW, Zhao W, Zhong JJ. Biotechnological production and application of ganoderic acids. Appl Microbiol Biotechnol. 2010;87:457\u201366.","journal-title":"Appl Microbiol Biotechnol"},{"key":"329_CR18","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s10529-005-6191-y","volume":"27","author":"HL Yang","year":"2005","unstructured":"Yang HL. Ganoderic acid produced from submerged culture of Ganoderma lucidum induces cell cycle arrest and cytotoxicity in human hepatoma cell line BEL7402. Biotechnol Lett. 2005;27:835\u20138.","journal-title":"Biotechnol Lett"},{"key":"329_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10:363\u20134.","journal-title":"Nat Med"},{"key":"329_CR20","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1096\/fj.201801338RRR","volume":"33","author":"W Wang","year":"2019","unstructured":"Wang W, Geng X, Lei L, Jia Y, Li Y, Zhou H, et al. Aquaporin-3 deficiency slows cyst enlargement in experimental mouse models of autosomal dominant polycystic kidney disease. FASEB J. 2019;33:6185\u201396.","journal-title":"FASEB J"},{"key":"329_CR21","doi-asserted-by":"publisher","first-page":"F1234","DOI":"10.1152\/ajprenal.00356.2011","volume":"302","author":"H Zhou","year":"2012","unstructured":"Zhou H, Gao J, Zhou L, Li X, Li W, Li X, et al. Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models. Am J Physiol Ren Physiol. 2012;302:F1234\u201342.","journal-title":"Am J Physiol Ren Physiol"},{"key":"329_CR22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/aps.2011.29","volume":"32","author":"Y Sun","year":"2011","unstructured":"Sun Y, Zhou H, Yang BX. Drug discovery for polycystic kidney disease. Acta Pharmacol Sin. 2011;32:805\u201316.","journal-title":"Acta Pharmacol Sin"},{"key":"329_CR23","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1096\/fj.14-260828","volume":"29","author":"W Wang","year":"2015","unstructured":"Wang W, Li F, Sun Y, Lei L, Zhou H, Lei T, et al. Aquaporin-1 retards renal cyst development in polycystic kidney disease by inhibition of Wnt signaling. FASEB J. 2015;29:1551\u201363.","journal-title":"FASEB J"},{"key":"329_CR24","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.bbadis.2017.03.012","volume":"1863","author":"L Lei","year":"2017","unstructured":"Lei L, Wang W, Jia Y, Su L, Zhou H, Verkman AS, et al. Aquaporin-3 deletion in mice results in renal collecting duct abnormalities and worsens ischemia-reperfusion injury. Biochim Biophys Acta, Mol Basis Dis. 2017;1863:1231\u201341.","journal-title":"Biochim Biophys Acta, Mol Basis Dis"},{"key":"329_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejmech.2019.04.039","volume":"174","author":"C Liang","year":"2019","unstructured":"Liang C, Tian D, Liu Y, Li H, Zhu J, Li M, et al. Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y. Eur J Med Chem. 2019;174:130\u201341.","journal-title":"Eur J Med Chem"},{"key":"329_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/hlca.19820650221","volume":"65","author":"T Kubota","year":"1982","unstructured":"Kubota T, Asaka Y, Miura I, Mori H. Structures of ganoderic acid A and B, two new lanostane type bitter triterpenes from Ganoderma lucidum (FR.) KARST. Helv Chim Acta. 1982;65:611\u20139.","journal-title":"Helv Chim Acta"},{"issue":"9","key":"329_CR27","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1248\/cpb.34.3695","volume":"34","author":"TOHRU KIKUCHI","year":"1986","unstructured":"Kikuchi T, Kanomi S, Kadota S, Murai Y, Tsubono K, Ogita ZI. Constituents of the fungus Ganoderma lucidum (Fr.) Karst. I Structures of ganoderic acids C2, E, I, and K, lucidenic acid F and related compounds. Chem Pharm Bull.\u00a01986;34:3695\u2013712.","journal-title":"CHEMICAL & PHARMACEUTICAL BULLETIN"},{"key":"329_CR28","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1248\/cpb.33.2624","volume":"33","author":"T Kikuchi","year":"1985","unstructured":"Kikuchi T, Matsuda S, Kadota S, Murai Y, Ogita Z. Ganoderic acid D, E, F, and H and lucidenic acid D, E, and F, new triterpenoids from Ganoderma lucidum. Chem Pharm Bull. 1985;33:2624\u20137.","journal-title":"Chem Pharm Bull"},{"key":"329_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1074\/mcp.M700259-MCP200","volume":"7","author":"QX Yue","year":"2008","unstructured":"Yue QX, Cao ZW, Guan SH, Liu XH, Tao L, Wu WY, et al. Proteomics characterization of the cytotoxicity mechanism of ganoderic acid D and computer-automated estimation of the possible drug target network. Mol Cell Proteom. 2008;7:949\u201361.","journal-title":"Mol Cell Proteom"},{"key":"329_CR30","first-page":"1908","volume":"42","author":"XQ Che","year":"2017","unstructured":"Che XQ, Li SP, Zhao J. Ganoderma triterpenoids from aqueous extract of Ganoderma lucidum. Zhongguo Zhong Yao Za Zhi. 2017;42:1908\u201315.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"329_CR31","first-page":"3599","volume":"37","author":"BM Li","year":"2012","unstructured":"Li BM, Gu HF, Li Y, Liu C, Wang HQ, Kang J, et al. Determination of nine triterpenoid acids from Ganoderma lucidum of different producting areas by HPLC. Zhongguo Zhong Yao Za Zhi. 2012;37:3599\u2013603.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"329_CR32","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3892\/ijo.2015.2925","volume":"46","author":"DL Liu","year":"2015","unstructured":"Liu DL, Li YJ, Yang DH, Wang CR, Xu J, Yao N, et al. Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2\/ADM cells. Int J Oncol. 2015;46:2029\u201338.","journal-title":"Int J Oncol"},{"key":"329_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2008.11.005","volume":"602","author":"I Miyamoto","year":"2009","unstructured":"Miyamoto I, Liu J, Shimizu K, Sato M, Kukita A, Kukita T, et al. Regulation of osteoclastogenesis by ganoderic acid DM isolated from Ganoderma lucidum. Eur J Pharmacol. 2009;602:1\u20137.","journal-title":"Eur J Pharmacol"},{"key":"329_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.lfs.2006.09.001","volume":"80","author":"W Tang","year":"2006","unstructured":"Tang W, Liu JW, Zhao WM, Wei DZ, Zhong JJ. Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci. 2006;80:205\u201311.","journal-title":"Life Sci"},{"key":"329_CR35","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s11033-016-4074-z","volume":"43","author":"BS Gill","year":"2016","unstructured":"Gill BS, Kumar S, Navgeet. Evaluating anti-oxidant potential of ganoderic acid A in STAT 3 pathway in prostate cancer. Mol Biol Rep. 2016;43:1411\u201322.","journal-title":"Mol Biol Rep"},{"key":"329_CR36","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1055\/s-0032-1315303","volume":"78","author":"X Yao","year":"2012","unstructured":"Yao X, Li G, Xu H, Lu C. Inhibition of the JAK-STAT3 signaling pathway by ganoderic acid A enhances chemosensitivity of HepG2 cells to cisplatin. Planta Med. 2012;78:1740\u20138.","journal-title":"Planta Med"},{"key":"329_CR37","first-page":"577","volume":"21","author":"J Jiang","year":"2008","unstructured":"Jiang J, Grieb B, Thyagarajan A, Sliva D. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. Int J Mol Med. 2008;21:577\u201384.","journal-title":"Int J Mol Med"},{"key":"329_CR38","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1128\/MCB.26.6.2262-2272.2006","volume":"26","author":"LK Rushworth","year":"2006","unstructured":"Rushworth LK, Hindley AD, O\u2019Neill E, Kolch W. Regulation and role of Raf-1\/B-Raf heterodimerization. Mol Cell Biol. 2006;26:2262\u201372.","journal-title":"Mol Cell Biol"},{"key":"329_CR39","doi-asserted-by":"publisher","first-page":"C522","DOI":"10.1152\/ajpcell.00163.2010","volume":"301","author":"J Elliott","year":"2011","unstructured":"Elliott J, Zheleznova NN, Wilson PD. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol Cell Physiol. 2011;301:C522\u20139.","journal-title":"Am J Physiol Cell Physiol"},{"key":"329_CR40","first-page":"101","volume":"8","author":"FR Cao","year":"2017","unstructured":"Cao FR, Feng L, Ye LH, Wang LS, Xiao BX, Tao X, et al. Ganoderic acid A metabolites and their metabolic kinetics. Front Pharmacol. 2017;8:101.","journal-title":"Front Pharmacol"},{"key":"329_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jchromb.2017.03.009","volume":"1052","author":"FR Cao","year":"2017","unstructured":"Cao FR, Xiao BX, Wang LS, Tao X, Yan MZ, Pan RL, et al. Plasma and brain pharmacokinetics of ganoderic acid A in rats determined by a developed UFLC-MS\/MS method. J Chromatogr B Anal Technol Biomed Life Sci. 2017;1052:19\u201326.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"329_CR42","doi-asserted-by":"publisher","unstructured":"Lu J, Qin JZ, Chen P, Chen X, Zhang YZ, Zhao SJ. Quality difference study of six varieties of Ganoderma lucidum with different origins. Front Pharmacol. 2012;3:57.\u00a0https:\/\/doi.org\/10.3389\/fphar.2012.00057.","DOI":"10.3389\/fphar.2012.00057"},{"key":"329_CR43","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s11418-018-1213-y","volume":"72","author":"T Nakagawa","year":"2018","unstructured":"Nakagawa T, Zhu Q, Tamrakar S, Amen Y, Mori Y, Suhara H, et al. Changes in content of triterpenoids and polysaccharides in Ganoderma lingzhi at different growth stages. J Nat Med. 2018;72:734\u201344.","journal-title":"J Nat Med"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0329-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:35Z","timestamp":1684616555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-019-0329-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1038\/s41401-019-0329-2","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,7]]},"assertion":[{"value":"25 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}